Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Multiple Oral Doses of BAY1830839 in Healthy Men
NCT03965728Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in immune-mediated inflammatory diseases (IMID) comparing BAY1830839 arm with Placebo arm (2 arms). Primary endpoints: Frequency of Treatment-Emergent Adverse Events at 18 days, Severity of Treatment-Emergent Adverse Events at 18 days and 8 more. Started Jun 2019; status: completed.
02
Drugs
BAY1830839
03
Conditions
immune-mediated inflammatory diseases (IMID)
Beyond the preview
Go deeper on NCT03965728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03965728.